The stock of Premaitha Health PLC (LON:NIPT) is a huge mover today! The stock decreased 4.74% or GBX 0.41 on November 22, hitting GBX 8.34. About 732,529 shares traded hands or 11.49% up from the average. Premaitha Health PLC (LON:NIPT) has declined 11.39% since April 22, 2016 and is downtrending. It has underperformed by 15.95% the S&P500.
The move comes after 8 months positive chart setup for the GBX 19.31 million company. It was reported on Nov, 22 by Barchart.com. We have GBX 8.59 PT which if reached, will make LON:NIPT worth GBX 579,300 more.
Premaitha Health PLC (LON:NIPT) Ratings Coverage
Out of 2 analysts covering Premaitha Health Plc (LON:NIPT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Premaitha Health Plc has been the topic of 28 analyst reports since September 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Panmure Gordon given on Tuesday, March 29. The stock of Premaitha Health PLC (LON:NIPT) has “Corporate” rating given on Monday, June 6 by FinnCap. The firm earned “Corporate” rating on Tuesday, August 30 by FinnCap. The stock of Premaitha Health PLC (LON:NIPT) has “Buy” rating given on Monday, July 4 by Panmure Gordon. FinnCap maintained the shares of NIPT in a report on Monday, November 21 with “Corporate” rating. As per Tuesday, February 2, the company rating was maintained by Panmure Gordon. FinnCap maintained Premaitha Health PLC (LON:NIPT) rating on Monday, October 31. FinnCap has “Corporate” rating and GBX 20 price target. The firm has “Buy” rating by Panmure Gordon given on Tuesday, September 22. The company was maintained on Wednesday, March 9 by FinnCap. The firm has “Corporate” rating by FinnCap given on Monday, March 21.
More news for Premaitha Health PLC (LON:NIPT) were recently published by: Businesswire.com, which released: “Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo …” on December 14, 2015. Uk.Finance.Yahoo.com‘s article titled: “Premaitha Health PLC (NIPT.L)” and published on July 07, 2014 is yet another important article.
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The company has a market cap of 19.31 million GBP. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. It currently has negative earnings. The IONA test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.